| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Jürgen Mestan | |
| Sandra W Cowan-Jacob | |||
| Paul William Manley | |||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| structural biology | Q908902 | ||
| P304 | page(s) | 3-13 | |
| P577 | publication date | 2005-12-30 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia | |
| P478 | volume | 1754 |
| Q36892617 | A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia |
| Q33817421 | A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors |
| Q39235281 | An overview of quinoline as a privileged scaffold in cancer drug discovery |
| Q41980844 | BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia |
| Q42222524 | Bcr-Abl tyrosine kinase inhibitors- current status |
| Q38133575 | Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era. |
| Q39516382 | Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? |
| Q36731265 | Chronic Myeloid Leukaemia in The 21st Century |
| Q37163550 | Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet |
| Q37498272 | Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia |
| Q83834361 | Clone wars in CML |
| Q81241473 | Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis |
| Q36801573 | Discoidin domain receptor-1 and periostin: new players in chronic kidney disease |
| Q30489704 | Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors |
| Q53054357 | Effect of nilotinib on airway remodeling in a murine model of chronic asthma. |
| Q54365521 | Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. |
| Q36445910 | Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. |
| Q92631070 | Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases |
| Q39657684 | Expanding the Diversity of Allosteric Bcr-Abl Inhibitors |
| Q33285468 | Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. |
| Q46079038 | In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. |
| Q35071010 | Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. |
| Q36997348 | Ligand binding site identification by higher dimension molecular dynamics |
| Q38081983 | Management of gastrointestinal stromal tumors |
| Q46703844 | Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations |
| Q38166071 | Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury |
| Q42015762 | Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease |
| Q34130343 | Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review |
| Q90190658 | Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma |
| Q36906387 | Nilotinib-Induced Keratosis Pilaris |
| Q39768989 | Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors |
| Q37763106 | Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents |
| Q48168059 | Pathological role of a point mutation (T315I) in BCR-ABL1 protein-A computational insight. |
| Q40252880 | Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors |
| Q38957115 | Pneumatosis intestinalis during chemotherapy with nilotinib in a patient with chronic myeloid leukemia who tested positive for anti-topoisomerase I antibodies |
| Q41130127 | Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 |
| Q43213931 | Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry |
| Q35242120 | Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin |
| Q37118177 | Reengineering dendritic cell-based anti-cancer vaccines |
| Q38841623 | Ruxolitinib induces autophagy in chronic myeloid leukemia cells. |
| Q34622576 | Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia |
| Q41002630 | Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS. |
| Q37235024 | Somatic pharmacogenomics in cancer |
| Q44296766 | Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. |
| Q27640723 | Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia |
| Q29547395 | Targeting cancer with small molecule kinase inhibitors |
| Q36983136 | Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer |
| Q37896606 | The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose |
| Q94544586 | The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib |
| Q37139171 | The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors |
| Q36498802 | The second generation of BCR-ABL tyrosine kinase inhibitors |
| Q37406014 | Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? |
| Q52567954 | Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making. |
| Q27478101 | c-Src protein kinase inhibitors block assembly and maturation of dengue virus |
Search more.